Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | CTH | P32929 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20470009 | 1.00 | EGLN1 (0.43) | EGLN1APEX1ALDH1A1MAPTTDP1 | |
| SCHEMBL1329823 | 0.97 | EGLN1 (0.44) | EGLN1APEX1ALDH1A1MAPTTDP1 | |
| SCHEMBL23641747 | 0.85 | EGLN1 (0.36) | EGLN1APEX1ALDH1A1MAPTTDP1 | |
| SCHEMBL30744226 | 0.82 | ECE1 (0.50) | EGLN1MAPTFAAHMEN1KMT2A | |
| SCHEMBL22064537 | 0.82 | CA1 (0.38) | ALDH1A1LMNARECQLCA1CA2 | |
| SCHEMBL1463416 | 0.82 | CA1 (0.38) | ALDH1A1LMNARECQLCA1CA2 | |
| SCHEMBL21440819 | 0.80 | CA1 (0.37) | ALDH1A1TDP1RECQLCA1CA2 | |
| SCHEMBL21440849 | 0.80 | CA1 (0.37) | ALDH1A1TDP1RECQLCA1CA2 | |
| SCHEMBL21440852 | 0.80 | CA1 (0.37) | ALDH1A1TDP1RECQLCA1CA2 | |
| SCHEMBL468870 | 0.80 | CTH (0.44) | EGLN1APEX1ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-11826387-B2 | Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells | PROTOKINETIX INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-3831823-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831824-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-10688193-B2 | PH-sensitive linkers for delivering a therapeutic agent | GNT BIOTECH & MEDICALS CORPORATION (TW) | 2020-06-23 | — | — | US | disclosed |
| WO-2020025030-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024997-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
| US-20180221498-A1 | PH-SENSITIVE LINKERS FOR DELIVERING A THERAPEUTIC AGENT | GNT BIOTECH & MEDICALS CORPORATION (TW) | 2018-08-09 | — | — | US | disclosed |
| EP-2392579-B1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | OTSUKA CHEMICAL CO LTD (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8993536-B2 | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same | OTSUKA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-2392579-A1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | Otsuka Chemical Holdings Co., Ltd. (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20110281819-A1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826387-B2 | Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells | GMFG, GLA, GLB1 | EGLN1 1720/4885APEX1 3309/4885ALDH1A1 280/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | EGLN1 4137/4885APEX1 774/4885ALDH1A1 2397/4885 |
| US-20110281819-A1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | HRH1, HRH2, HRH3 | EGLN1 960/4885APEX1 4486/4885ALDH1A1 1422/4885 |
| US-10688193-B2 | PH-sensitive linkers for delivering a therapeutic agent | CD47, CD44, ASIC1 | EGLN1 1122/4885APEX1 478/4885ALDH1A1 2165/4885 |
| US-20180221498-A1 | PH-SENSITIVE LINKERS FOR DELIVERING A THERAPEUTIC AGENT | CD47, CD44, ASIC1 | EGLN1 1122/4885APEX1 478/4885ALDH1A1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.